Background-Echocardiography is commonly used to direct the management of hypertensive disorders in medical patients, but its application in pregnancy is unclear. Our objective was to define the use of echocardiography in pregnancies complicated by gestational hypertension (GH) and preeclampsia. Methods and Results-We performed a systematic review of articles using an electronic search of databases from inception to March 2015, prospectively registered with PROSPERO (CRD42015015700). Eligible studies included pregnant women with GH or preeclampsia, evaluating left ventricular structure and function using echocardiography. The search strategy identified 36 studies, including 745 women with GH and 815 women with preeclampsia. The populations were heterogeneous with respect to clinical characteristics, parity, and risk of bias. Increased vascular resistance and left ventricular mass were the most consistent findings in GH and preeclampsia. Differentiating features from normal pregnancy were left ventricular wall thickness of ≥1.0 cm, exaggerated reduction in E/A, and lateral e′ of <14 cm/s. There was disagreement between studies with regard to cardiac output because of the timing of echocardiography, although reduced stroke volume was an indicator of adverse prognosis. Diastolic dysfunction and left ventricular remodeling are most marked in severe and early-onset preeclampsia, but are also markers of preeclampsia before clinical manifestation, and are associated with adverse outcomes. Conclusions-Echocardiography is a valuable tool to stratify risk and can guide management and counseling in the preclinical and clinical phases of GH and preeclampsia. Changes in cardiac function and morphology are recognizable at an asymptomatic early stage and correlate with disease severity and adverse outcomes. (Circ Cardiovasc Imaging. 2016;9:e004888.
C ardiac disease is the leading non-obstetric cause of death in pregnancy and the puerperium. 1 In uncomplicated pregnancy, there is no significant change in systolic blood pressure. 2, 3 Diastolic blood pressure and mean arterial pressure decrease during the first trimester and then plateau in the second trimester before rising in the final weeks of pregnancy. 2, 3 Hypertension is seen in 6% to 8% of pregnancies 4 and the incidence is increasing as the obstetric population becomes older and more obese. 5 Hypertension causes one third of severe maternal morbidity 4 and is the second most common direct cause of maternal mortality worldwide, accounting for ≈14% of maternal deaths. 6 Adverse fetal outcomes include preterm birth, growth restriction, and stillbirth. 4
See Clinical Perspective
The hypertensive disorders specific to pregnancy are gestational hypertension (GH) and preeclampsia. Guidelines and terminology vary across the world. 4, [7] [8] [9] [10] The diagnosis and classification of these conditions depend on the gestation at which elevated blood pressure is identified (GH and preeclampsia are acquired conditions in the second half of pregnancy), the presence or absence of multisystem involvement or significant proteinuria (traditionally the hallmark of preeclampsia 4 ), and whether the blood pressure normalizes in the postnatal period. The onset of hypertension in GH and preeclampsia must be after 20 weeks of gestation to distinguish them from chronic hypertension. Preeclampsia can develop in patients with GH and also be superimposed on chronic hypertension.
Understanding the structure and function of the heart in pregnancy is vital if we are to recognize abnormalities at an early stage and plan appropriate interventions to avoid adverse outcomes. Echocardiography is a safe, noninvasive technique to assess cardiac structure and function in pregnancy. [11] [12] [13] [14] Although operator dependent and requiring training to provide reproducible measurements, 11 the temporal variability of echocardiography is small. 15 Modern ultrasound technologies can demonstrate subtle changes in cardiac geometry and performance, [16] [17] [18] [19] and echocardiography has important potential for longitudinal assessment in view of its noninvasive nature. However, evidence for the role of echocardiography for serial measurements in pregnancy is lacking, and despite common use in clinical practice, the application of echocardiography to study hypertensive disorders of pregnancy is inconsistent.
Our aim was to systematically review the current literature to assess changes in echocardiographic structure and function in women developing GH and preeclampsia. We hypothesized that echocardiography would be a useful screening tool to identify (1) high-risk women in whom recognizable cardiovascular changes occur before manifesting clinically as a hypertensive disorder and (2) women at increased risk after a diagnosis of GH or preeclampsia.
Methods

Information Sources and Search Strategy
Studies using echocardiography in pregnancies complicated by GH or preeclampsia were eligible for inclusion in our systematic review. The definitions of GH and preeclampsia used by each individual study were accepted. Figure 1 shows a typical algorithm for the classification of hypertensive disorders of pregnancy. Our search included MEDLINE, EMBASE, CINAHL, and the Cochrane Library from inception to March 2015, as well as relevant reference lists. The MEDLINE search strategy is shown in Table I in the Data Supplement and was adapted for the requirements of the other databases. There was no restriction on the type of study design or publication language. Full-text articles were obtained after screening the title or abstract of eligible studies by 2 authors (J.S.C. and F.T.). The review process was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist 20 and prospectively registered with the PROSPERO database (CRD42015015700; http://www.crd. york.ac.uk/PROSPERO/DisplayPDF.php?ID=CRD42015015700).
Eligibility Criteria and Study Selection
The population of interest was pregnant women with GH or preeclampsia. Our inclusion criteria required an echocardiogram during pregnancy (before or after the diagnosis of GH/preeclampsia). Pregnant women with normal blood pressure were included as a comparison group. The exclusion criteria were as follows: (1) studies published only in abstract form; (2) duplicate publications or publications using the same data set (in the latter case only the largest study including the same patients would be included, unless different data were presented in each article); (3) case reports, editorials, opinion articles, commentaries, and letters; (4) animal studies; (5) studies including only multiple pregnancies; (6) studies assessing therapeutic effects; and (7) studies of pregnant women with chronic hypertension, unless a group with GH or preeclampsia were also included.
Data Collection, Outcomes, and Quality Assessment
A standardized data extraction form was used. Outcome measures included any echocardiographic assessment of left ventricular (LV) structure or function (Table II and Figure I in the Data Supplement). The RoBANS (Risk of Bias Assessment Tool for Non-Randomized Studies) 21 was used to critique methodological and reporting quality of the included articles, addressing key criteria such as selection bias, exposure measurement, blinding, the completeness of outcome data and selectivity of reporting. Two authors (J.S.C. and F.T.) completed the data quality assessment independently, and any disagreements were resolved by consensus.
Data Synthesis
Statistical pooling of data from separate studies was not possible because of marked variation in study design and reported outcome measures, thus precluding meta-analysis. Therefore, data were synthesized qualitatively.
Results
Study Selection and Study Characteristics
The search strategy identified 36 studies, including 745 women with GH and 815 women with preeclampsia and 7189 normotensive pregnant controls ( Figure 2 ). The characteristics of included studies are shown in Table 1 .
All studies had an observational design, with 25 case-control studies, 33-57 8 cross-sectional studies, [25] [26] [27] [28] [29] [30] [31] [32] and 3 longitudinal cohort studies. [22] [23] [24] The majority of studies (n=20) were of women with preeclampsia. 23, [26] [27] [28] [29] [30] 33, 38, [40] [41] [42] 44, [50] [51] [52] [53] [55] [56] [57] There were 9 studies assessing GH only 24, 32, 35, 37, 39, 43, 48, 49, 54 and 7 studies evaluating both GH and preeclampsia. 22, 25, 31, 34, 36, 43, 45 All investigators recruited women during antenatal visits to hospital. In 3 of the studies where women were scanned before the onset of hypertension, the women had already been identified as a highrisk group because of fetal growth restriction, 29 raised uterine artery Doppler, 46 or preeclampsia in a previous pregnancy. 23 The majority of studies investigated patients with a single echocardiogram during the third trimester (n=29). Of the 3 longitudinal studies, 1 included echocardiography in each trimester 22 and the other 2 covered 2 trimesters. 23, 24 Considerable heterogeneity was seen between and within the study populations ( Table 2) , such that meta-analysis was not considered appropriate. In 6 studies, a proportion of the patients were on antihypertensive therapy. [23] [24] [25] 44, 50, 54 In 2 studies, the preeclampsia group included a small number of women with chronic hypertension and superimposed preeclampsia. 23, 25 Other obstetric outcomes, for example, birthweight and gestation at delivery, were recorded in 15 of the studies. 22, 23, [26] [27] [28] [29] 31, 32, 40, 42, 45, 50, 51, 56, 57 Only 3 studies analyzed the relationship between these pregnancy outcomes and echocardiographic measurements 32, 42, 45 (Table III in the Data Supplement).
The risk of bias assessment identified variable study quality (Table IV in the Data Supplement). Because of the nature of the studies, the risk of specific biases (particularly blinding) was uncertain because of limited reporting in the individual studies.
Synthesis of Results
Results are summarized below according to hemodynamic parameters and systolic function, diastolic function, and cardiac structure. Table 3 presents an overview of findings for the main echocardiographic variables investigated in the third trimester studies. The details of extracted parameters from all studies (including the earlier screening studies) are presented in Table V in the Data Supplement. Figure 3 highlights the major echocardiographic changes that may be seen in hypertensive disorders when compared with normal pregnancy. 
Hemodynamics and Systolic Function
Total vascular resistance was significantly higher in GH compared with normotensive pregnant controls 22, 36, 47, 48, 54 but lower than in those with preeclampsia. 22, 43 In GH, there were conflicting reports for cardiac output, including an increase 22, 24, 25, 34 or no change compared with normal pregnancy. 36, 47, 48 Myocardial performance index and LV function were unchanged in a longitudinal study of GH with second and third trimester measurements. 24 In GH studies with a third trimester echocardiogram, only 1 showed a significant reduction in LV ejection fraction, 48 whereas 3 others showed no difference. 24, 35, 48 In preeclampsia, studies covering early trimesters demonstrated that the preclinical phase is characterized by a hyperdynamic circulation with high cardiac output and low peripheral resistance. 22, [25] [26] [27] In the second trimester, women who go on to develop preeclampsia have increased total vascular resistance at midgestation, with lower cardiac output. 27, 28 Once preeclampsia manifests clinically, there is reduced cardiac output and increased resistance, 22, 30 described as a hemodynamic crossover in the clinical phase of preeclampsia. 22 The increased total vascular resistance seen in preeclampsia 29, 30, 34, 38, 43, 51 is an independent predictor of adverse maternal and fetal outcomes. 32 In the clinical phase, early-onset preeclampsia (<34 weeks of gestation) is characterized by significantly lower cardiac output and higher total vascular resistance compared with late-onset preeclampsia. 27, 28 Pregnant women who develop recurrent preeclampsia have also been shown to have lower cardiac output and higher peripheral resistance than women without recurrent disease. 23 Stroke volume is lower in preeclampsia than in normal pregnancy 42, 43 ; in the first trimester, this is an independent predictor of subsequent development of preeclampsia. 26 Because of the factors discussed, cardiac output in preeclampsia has been shown to be both lower 29, 30, 34, 38, 42, 50 and higher 25, 26, 38, 43, 51 than normotensive pregnancies. The variation in cardiac output is shown in Table V in the Data Supplement, which also indicates its derivation. The use of different calculations (based either on Doppler or volume calculation) is likely to contribute to the disparity for this parameter. There was similar variability with regard to LV ejection fraction, with the majority of studies showing no significant difference compared with normotensive pregnant women 30, 38, 52, 56, 57 and only 1 showing a decrease. 33 Myocardial performance index was reduced in a study of women with preeclampsia and fetal growth restriction in the third trimester. 29 Systolic dysfunction, with marked LV hypertrophy, is significantly more common in preterm preeclampsia than in term preeclampsia, 46 even before the condition manifests clinically. 27
Diastolic Function
Several studies have shown that in normal pregnancy, the E/A ratio decreases toward term. 3, 17, 58, 60, 61 A greater reduction in E/A has been shown in GH than in pregnancy unaffected by hypertension. 24, 35, 47, 48, 55 Diastolic function is also impaired in preeclampsia, 40, 46, 53 where the usual reduction in E/A is exaggerated. 33, 40, 46, 55 The ratio of early diastolic mitral inflow velocity:early diastolic mitral annular velocity (E/e′) was significantly higher in women with preeclampsia in 5 studies, suggesting higher LV filling pressures. 27, 38, 40, 53, 57 Interestingly E/e′ was shown to be significantly higher in an early-onset preeclampsia subgroup compared with a late-onset subgroup. 40 One study used a composite of diastolic indices to diagnose diastolic dysfunction and demonstrated diastolic dysfunction in 40% of pregnancies complicated by preeclampsia at term, compared with 14% of controls. 45 In another study, diastolic dysfunction was already present at 20 to 23 weeks in women who developed preterm preeclampsia, but not in women who developed preeclampsia at term. 27 Diastolic dysfunction in 3 Oren, 1996 48 Data are presented as means±SD or medians (interquartile range). DBP indicates diastolic blood pressure; GH, gestational hypertension; NTP, normotensive pregnant control; PET, preeclampsia; SBP, systolic blood pressure; and SGA, small for gestational age fetus. preeclampsia is more marked in cases associated with fetal growth restriction, 29 despite evidence that left atrial mechanical function is similar in preeclampsia and normotensive pregnant controls. 41
Cardiac Structure and Remodeling
In most studies, LV mass was significantly increased in GH compared with normotensive pregnant controls in the second 48 and third trimesters 35, 37, 39, 47, 48, 54 and increased in the second half of pregnancy when measured serially. 24 One study identified ventricular remodeling or hypertrophy in 91% of patients with GH. 47 The concentric hypertrophy seen in GH 35, 37 is an independent predictor of adverse pregnancy outcomes. 32 Other investigators found no change in LV mass in GH, showing this instead to be a feature of chronic hypertension. 49, 52 LV/left atrial diameters were increased in GH compared with normotensive controls. 38, 55 LV remodeling is more common in preeclampsia than in normotensive pregnant women in the third trimester, 56 with numerous studies confirming increased LV mass in preeclampsia. 33, 35, 38, 40, 41, 45, 50 Hypertrophy in preeclampsia tends to be of the concentric type 50 and has been shown in preterm 33, 40, 46 and term preeclampsia. 41, 45, 46, 55 In 1 study, concentric LV remodeling was demonstrated at 20 to 23 weeks of gestation in 33% of women who subsequently developed preeclampsia. 27 In women who progressed to preeclampsia from GH, 27% had abnormal LV structure and function at the time of echocardiography. 35 
Discussion
We performed a systematic review of all the literature pertaining to the use of echocardiography in pregnant women with a hypertensive disorder. Our major findings were increased peripheral resistance in GH and preeclampsia, Thompson, 1986 52 Data are presented as means±SD or medians (interquartile range). CI indicates confidence interval; Comp., complicated; GH, gestational hypertension; n/a, not applicable; NTP, normotensive pregnant control; P, parity; PET, preeclampsia; SGA, small for gestational age fetus; and uncomp., uncomplicated.
*Definition of GH could include patients with PET. †GH group includes patients with essential hypertension. 29 Borghi, 2000 33 Borghi, 2011 34 Cho, 2011 35 Degani, 1989 36 Demir, 2003 37 * ‡ Dennis, 2012 38 Escudero, 1988 39 Estensen, 2013 30 * ‡ Hamad, 2009 40 Ingec, 2005 41 Kuzniar, 1982 42 Kuzniar, 1992 43 * ‡
diastolic dysfunction in preeclampsia, and conflicting evidence on changes in cardiac output. The echocardiographic changes in cardiac structure and function can be detected before the condition is clinically apparent. Current evidence suggests that alterations in preeclampsia are not because of hypertension alone, but rather reflect preeclampsia as a multisystem disorder. Preeclampsia has a greater impact on the heart than GH, and changes are most pronounced in early onset, severe disease. Currently, echocardiography is not widely used in the clinical management of hypertensive disorders in pregnancy or as a screening tool for preeclampsia. The application of echocardiography in pregnancy has traditionally been in patients with adult congenital cardiac disease, in acute illness, or for research purposes. The management of hypertensive disorders in pregnancy is based on maternal clinical assessment (symptoms, blood pressure, and laboratory parameters) and fetal wellbeing. A decision to deliver the baby can be for maternal or fetal reasons. Whereas other reviews have focused on congenital heart disease 62 or described echocardiographic changes in the context of a broad overview of the management of preeclampsia, 63 ours is the first systematic review of cardiac structure and function in gestational hypertensive disease.
Clinicians now recognize that preeclampsia should no longer be considered as a single disease process. There is evidence to suggest that preterm hypertension and proteinuria associated with fetal growth restriction is different from hypertension and proteinuria at term when birthweights tend to be normal or increased. 64 The possible difference in the mechanism of disease and how it manifests clinically 65 may be responsible for the conflicting results between studies when early-and late-onset preeclampsia are considered as 1 entity. The contradictory hemodynamic models described can be explained by noting the distinction between early preeclampsia 27, 28 and late-onset disease. 22, 32 Although based on observational data, our review suggests that echocardiography has the potential to improve the management of patients with hypertension during pregnancy and categorize patients with GH or preeclampsia into high-and low-risk groups. Patients with increased vascular resistance and LV mass are more likely to have complications. 32 As a predictor of long-term cardiovascular morbidity, diastolic dysfunction in pregnancy is important to identify, 45 and reduced e′ (and therefore elevated E/e′) may be a useful and early predictor of preeclampsia. 29 Echocardiography can also help to identify the small numbers of women with LV systolic impairment who are more likely to deteriorate during pregnancy or postpartum. With the currently available data, we suggest the most efficient use of echocardiography is after the diagnosis of hypertension, to direct resources to the most vulnerable patients to improve maternal (and fetal) outcomes (Figure 4) . The optimal timing of echocardiography needs further study. Whereas an early echocardiogram in the first and second trimesters may be helpful for risk stratification, the available data on clinical impact are currently limited.
It has also been suggested that echocardiography can stratify hypertensive pregnant women into hemodynamic subgroups, thereby enabling clinicians to tailor their choice of antihypertensive therapy. 26 Hypertension characterized by vasoconstriction responds better to β-blockade, whereas in hypertension with reduced plasma volume, calcium channel blockers are preferable, as they reduce afterload and improve cardiac function. 67 Echocardiography can also have an important role in guiding fluid balance, one of the most challenging aspects in the management of preeclampsia. Overzealous fluid administration can lead to pulmonary edema, and conversely if a patient is underfilled, end-organ dysfunction may worsen. In selected centers and patients, myocardial strain imaging has been shown to be more sensitive than LV ejection fraction in detecting differences in LV systolic function in women with and without preeclampsia. 47 Strain measurements can potentially provide more information about cardiac function, but because of limited data 31, 44, 45, 50 further investigation is required.
In summary, echocardiography can reveal cardiac impairment in GH and preeclampsia, which changes antenatal management (medication, frequency of monitoring, and timing of delivery) and can indicate when postnatal followup is warranted. More longitudinal studies are required to evaluate the cardiovascular changes in hypertensive disorders throughout pregnancy and to further define the role of echocardiography in the antenatal assessment of women with GH and preeclampsia, and in subsequent pregnancies. It 54 Yuan, 2006 55 Yuan, 2014 56 Zieleskiewicz, 2014 57 
Limitations
The main limitation of our assessment was the wide variation in patient groups (age, ethnicity, body habitus, parity, timing of assessment, and disease severity) and reported outcome measures.
In several studies, the participants were grouped based on outcomes other than hypertensive disorder diagnosis. This heterogeneity restricts quantitative synthesis of results and meta-analysis. Many of the included studies involve small numbers of patients, with varying levels of risk for important bias and likely different levels of echocardiographer experience. A substantial amount of data is derived from load-dependent indices, which may be inferior to measurements that take into account the different loading conditions seen in pregnancy. The cross-sectional studies capture women at different stages of the disease and offer only a snapshot at a single point in time. At present, there is a paucity of longitudinal data in pregnancy. Only one of the longitudinal studies considered the reproducibility of the echocardiographic measurements, and while these results were encouraging (intraobserver variability 2.4% for cardiac output and 2.0% for total vascular resistance 22 ), further data in pregnant patients are clearly needed.
Conclusion
This systematic review demonstrates that cardiac structure and function using echocardiography are altered in the preclinical and clinical phases of GH and preeclampsia. For women with preeclampsia, diastolic dysfunction and increased peripheral vascular resistance correlate with disease severity. Recognition of impairment in cardiac function is important in the contemporary management of GH and preeclampsia, to improve pregnancy outcomes and long-term cardiovascular health.
